Skip to search formSkip to main contentSkip to account menu

Esomeprazole 20 MG / Naproxen 375 MG Delayed Release Oral Tablet [Vimovo]

Known as: Vimovo 375 MG / 20 MG Delayed Release Oral Tablet, Vimovo 375/20 (naproxen 375 MG / esomeprazole magnesium trihydrate 22.3 MG) Delayed Release Oral Tablet, NAPROXEN 375 mg / ESOMEPRAZOLE MAGNESIUM 20 mg ORAL TABLET, DELAYED RELEASE [VIMOVO] 
National Institutes of Health

Related topics

Related topics

24 relations
Croscarmellose SodiumDelayed Release Oral TabletEsomeprazoleEsomeprazole 20 MG

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and…
Background HCP1004 is a newly developed fixed-dose combination of naproxen (500 mg) and esomeprazole strontium (20 mg) that is… 
2013
2013
Vimovo ® : Fixed-dose naproxen/esomeprazole to treat arthritic symptoms
Vimovo ® tablets contain 500 mg naproxen and 20 mg esomeprazole. The product is indicated for symptomatic relief in the treatment… 
2012
2012
Fixed-dose naproxen/esomeprazole magnesium: a guide to its use to treat arthritic symptoms and reduce gastric ulcer risk
Oral naproxen/esomeprazole magnesium (Vimovo™) is a fixed-dose combination of an NSAID and a proton pump inhibitor. The… 
2011
2011
PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE ANTIPLATELET EFFECTS OF NAPROXEN AND ESOMEPRAZOLE MAGNESIUM (VIMOVO™) AND CONCOMITANT LOW-DOSE ASPIRIN
2010
2010
Vimovo™: (naproxen/esomeprazole magnesium) delayed-release tablets.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)